Back to Home

Wave Life Sciences

NASDAQ: WVE $6.16 USD ~$700M MCAP

Wave Life Sciences is a clinical-stage RNA medicines company using its proprietary PRISM platform to design stereopure oligonucleotides that target genetic diseases, metabolic disorders, and neurological conditions. Lead programs include WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD), WVE-003 for Huntington's disease, WVE-007 for obesity, and WVE-N531 for Duchenne muscular dystrophy, with a strategic collaboration with GSK to accelerate development of RNA-based therapeutics.

Company Info

Sector: Biotechnology / RNA Therapeutics
Headquarters: Cambridge, Massachusetts, USA
Founded: 2012

Upcoming Milestones & Key Dates

Late 2026
Clinical Trial

WVE-006 (AATD) proof-of-mechanism data in patients

Mid-2026
Clinical Trial

WVE-003 (Huntington's) updated safety and biomarker data

Clinical Development Pipeline

WVE-006

Target: A-to-I RNA editing oligonucleotide (AIMer)
Alpha-1 Antitrypsin Deficiency (AATD) (partnered with GSK)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

WVE-003

Target: Allele-selective antisense oligonucleotide
Huntington's disease (selectively targets mutant HTT allele)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

WVE-N531

Target: Exon 53 skipping oligonucleotide
Duchenne muscular dystrophy (DMD)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

WVE-007

Target: GalNAc-conjugated siRNA targeting INHBE in hepatocytes
Obesity (inhibits INHBE / Activin E for fat-mass reduction)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

No recent news updates available for this company.

Leadership Team

Paul Bolno, M.D., M.B.A.

President and Chief Executive Officer

Dr. Chandra Vargeese, Ph.D.

Chief Technology Officer

Dr. Erik Ingelsson, M.D., Ph.D., M.P.H.

Chief Medical Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now